Upperton appoint Philip Payne as Chief Commercial Officer

Press Release – Monday, 19th February, 2024.

Leading UK contract development and manufacturing organisation (CDMO) Upperton Pharma Solutions (Upperton) continues its growth following the build of a new 50,000 sq ft GMP manufacturing facility and recent sterile fill-finish capability announcement, with the appointment of Philip Payne as Chief Commercial Officer (CCO).

Philip joins Upperton’s leadership team and Board, following a recent investment in the company’s marketing and sales infrastructure.

Philip will work with Upperton’s leadership team and Board to drive the commercial strategy, leading the sales and marketing function and helping to guide the next stage of Upperton’s growth, including identification of new geographies and markets, supporting the continued growth of Upperton’s service offering into Europe and the US.

Philip has extensive experience in managing the integration of business development in an international environment across discovery, development, and manufacturing.

He joins Upperton following senior commercial roles at global pharmaceutical services companies including Abzena, Concept Life Sciences, Aptuit, and Catalent Pharma Solutions.

Philip said, “I am delighted to be joining Upperton. The company truly has a unique customer-focused culture that immediately made an impression. I look forward to working with the team to bring Upperton’s approach and experience to customers.”

Nikki Whitfield, CEO of Upperton Pharma Solutions, said, “Philip’s industry experience will be a great asset as we continue our expansion into new markets. He is a strong addition to our leadership team, providing strategic knowledge that will support our growth.”  


Philip Payne CCO Upperton

About Upperton Pharma Solutions:

Upperton Pharma Solutions has over 24 years of experience in delivering science-led, high-quality, innovative early drug development solutions to pharmaceutical and biotechnology clients worldwide. 

Based in Nottingham, UK, Upperton has formulation and analytical development laboratories, alongside a fully equipped GMP manufacturing facility and Quality Control testing capability, and is licensed by the MHRA to manufacture and test materials for clinical trials. In addition to supporting conventional oral solid dosage form development, Upperton has a strong history in spray drying which is applied to address both the challenges with poorly soluble molecules and as a particle engineering technology for targeted deposition for pulmonary and nasal drug products.

The company employs around 90 highly skilled personnel and has its headquarters in Nottingham, UK. 

Media assets:

Philip Payne Portrait Image, JPG, 563kb

For further information, images, and interview opportunities, please contact:
Rob Halliwell, Upperton Pharma Solutions
+44 (0) 115 855 7050